GHK-Cu has a small, varied human evidence base. A wound-care gel, a cosmetic serum and a compounded injection are different products. Non-injectable GHK-Cu appears in FDA Category 1, a conditional interim policy while the substance is evaluated; that is not FDA approval [10].
Match each claim to the population and product studied
Each use GHK-Cu is sold for has a different evidence base. The table gives selected human reports for each claim, how many people were in it, and what it showed.
| Claim | Selected evidence | People studied | What the evidence shows |
|---|---|---|---|
| Skin wrinkles and tone (topical) | Miller 2006, randomized trial | 13 completed | No blinded benefit; users rated skin better |
| Wound healing (topical gel) | Mulder 1994, randomized trial | Not given in the abstract | Faster ulcer closure in one trial |
| Scalp hair growth | Eyebrow findings do not establish scalp benefit | Different site and product | Not established |
| "Resets" aging genes | Computer and cell gene-expression analyses | 0 | Lab data only |
| Injected, body-wide effects | Kapoor 2018, open-label scalp injections of a six-ingredient mix | No controlled trial | Not shown; GHK-Cu effect can't be separated |
| Oral capsules or drops | No qualifying report in reviewed sources | Not established | No clinical benefit established here |
| Eyebrow enhancement | Bo 2026 randomized split-face report | 18 | Reported improvement at 12 weeks; preliminary, site-specific |
| Acne scars | Vignesh 2026 nonrandomized add-on study | 40 | No significant later between-group difference; more pigmentation |
These are selected reports, not an exhaustive inventory. Absence of adequate evidence is different from a negative trial.
Skin appearance: one small trial, no blinded benefit
In a 2006 randomized trial of 13 people after CO2 laser resurfacing, copper-peptide skin care made no difference that blinded evaluators or image software could measure, though users rated their skin quality better (P = .04) [3]. The full breakdown of that trial, and what a better one would look like, is in does topical GHK-Cu work.
Wound healing: a positive, product-specific result
A multicenter, evaluator-blinded, placebo-controlled trial of a GHK-Cu gel reported 98.5% median closure of diabetic foot ulcers, against 60.8% with the gel base alone [4]. All patients also got standard wound care. In ulcers treated right after debridement, infections ran 7% against 34%.
This was a wound-care gel tested like a drug, on open ulcers, in 1994. The abstract does not report how many patients took part, and the reviewed abstract alone cannot establish replication or a general cosmetic benefit. It supports GHK-Cu as a wound-healing agent worth more study. It says nothing about wrinkles, hair or aging.
Scalp-hair claims need site-specific evidence
A bibliographic search alone does not capture every topical report. Scalp-hair benefit needs scalp-specific controlled evidence; the eyebrow report discussed below cannot establish that claim.
The studies cited for hair tested mixtures. A 2024 open-label scalp study used a serum with five actives and was run with an author employed by the maker [5]. A 2018 single-arm pilot injected a formulation of six ingredients, including growth factors and thymosin beta-4 alongside copper tripeptide-1, into the scalp, with no control group [6]. Neither can show what GHK-Cu does by itself.
Newer topical reports answer narrower questions
A 40-person nonrandomized acne-scar study added copper peptide to dermarolling. Later between-group differences were not significant; hyperpigmentation occurred in 8 of 20 combination patients versus none with dermarolling alone. Allocation and baseline imbalance limit interpretation [1].
A preliminary 18-person randomized split-face report found eyebrow-count and diameter improvements after 12 weeks. Eyebrows, scalp hair and systemic injection claims are different questions; this result cannot answer them all [2].
"Resets aging genes" describes lab data, not people
The gene claims come from computer analyses of how cells respond in lab databases. Reviews by one research group, based at the company Skin Biology, report that GHK can raise or lower the activity of at least 4,000 human genes [7]. A 2017 review extends this to nervous-system genes, using the Broad Institute's Connectivity Map, a database of gene responses in cultured cells [8].
Moving genes in a cell line is not the same as a measurable benefit in a person. The reviewed clinical reports do not establish longer life, slower biological aging or improved cognition with GHK-Cu.
Isolated injected GHK-Cu: controlled benefit not established
The reviewed sources do not establish a controlled trial of isolated injected GHK-Cu for body-wide benefit. Kapoor’s 1,000-patient scalp report used six ingredients without a control, so neither the peptide’s contribution nor a systemic effect can be separated [6].
Its safety-risks page says compounded injectable GHK-Cu may pose a risk of immune reactions from clumping and impurities, and that there are limited data in humans [11]. The current Category 1 entry expressly excludes injections [10]. The separate legal history is explained in GHK-Cu FDA status.
Oral benefit is not established by the reviewed sources
The recorded PubMed query did not identify a qualifying human oral GHK-Cu trial [9]. A database search has coverage limits; it does not prove that no human exposure has ever occurred. No oral clinical benefit or reliable bioavailability is established here.
FDA's rules depend on how GHK-Cu is used
| Route | FDA position | Scope |
|---|---|---|
| Cosmetic skin care | Generally no premarket approval; color-additive rules are separate | Long-standing cosmetics law |
| Compounded topical or other non-injectable | 503A Category 1, under evaluation | Current May 14, 2026 entry; withdrawn in April and restored for non-injectable use |
| Compounded injectable | Outside non-injectable Category 1; nomination withdrawn after Category 2 | The current Category 1 entry excludes injection |
Current FDA categories and intended-use guidance; Category 1 is not approval.
The detailed history is in is GHK-Cu FDA-approved, and side effects in is GHK-Cu safe.
What would change the picture
Two things could move this page. FDA has said it will consult its compounding advisory committee about GHK-Cu before the end of February 2027 [10]. That is a decision about compounding, not proof that it works.
The evidence that would change the answer is a randomized, vehicle-controlled trial of GHK-Cu alone, with a stated strength, enough people and blinded measures. Larger confirmatory studies for skin aging and scalp hair would address broader marketing claims. Match each claim to the outcome actually tested. The questions this site asks of any provider selling it are in how we check.
Category 1 describes a conditional interim enforcement policy; other legal requirements still apply. It is not a finding that a particular compounded product is safe, effective or lawfully supplied in every circumstance. Product-specific pharmacy and plan questions are explained in how we check providers.
ClinicalTrials.gov lists NCT07437586 as recruiting, with 60 estimated participants and no posted results. Its paired-wound protocol compares topical GHK-Cu gel with vehicle and plans healing and safety assessments. Registration is a research plan, not evidence that treatment works or is safe [12].